Comparative Efficacy of 35 Disease-modifying Therapies in Relapsing-remitting MS: A Network Meta-analysis Identifying Top Performers for Relapse, MRI Activity, and Disability Progression

Real-world Tolerability, Safety, and Effectiveness of Ofatumumab in Adults With Multiple Sclerosis Over 36 Months

Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data

Reducing the Risk of PIRA in RRMS: The Value of High-efficacy Disease- Modifying Therapies